Actualités sur Economy

20.09.2007 – 13:10
Callisto Pharmaceuticals. Inc.
Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
New York (ots/PRNewswire) - Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders and diseases, announced today that complete enrollment of its Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine carcinoma (advanced carcinoid cancer) ...
plus
19.09.2007 – 23:33
Servier
New Data Confirm Clear Benefit of Protelos(R) (Strontium Ranelate) in the Treatment of Postmenopausal Osteoporosis
Honolulu, Hawaii (ots/PRNewswire) - - Protelos(R) Relaunches Bone Formation and Increases Bone Volume in Patients on Long Term Bisphosphonate Treatment Protelos(R) (strontium ranelate) stimulates bone formation and increases bone volume by 30% in high fracture risk patients who have been on long term ...
plus
19.09.2007 – 14:16
Takeda Pharmaceutical Company Limited
New Research Shows ACTOS(R) (pioglitazone HCI) is Associated With a 38% Lower Risk of Heart Attack in Type 2 Diabetes
Amsterdam (ots/PRNewswire) - - For Non-US Media Only New research, including two studies presented this week at the 43rd Annual Meeting of the European Association for the Study of Diabetes (EASD), further support the cardiovascular safety of ACTOS(R) (pioglitazone HCI) and its benefits regarding improved ...
plus
19.09.2007 – 14:10
IsoTis OrthoBiologics
IsoTis - Integra Merger
Irvine, California (ots/PRNewswire) - - Leading Proxy Advisor Recommends Shareholders Support Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that Institutional Shareholder Services, ISS, a leading proxy advisor, recommends shareholders support the merger of IsoTis and Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra"). For every M&A analysis, ISS reviews publicly available information and evaluates ...
plus
18.09.2007 – 11:24
Novasep
Groupe Novasep to Acquire PharmaChem Technologies (Grand Bahama) Ltd
Pompey, France (ots/PRNewswire) - - Combined Company Will Become one of the Leading Suppliers for the Life Science Industries Groupe Novasep announced today that the company is finalizing discussions to acquire Bahamas-based PharmaChem Technologies (Grand Bahama) Ltd for an undisclosed amount. The combination of Novasep and PharmaChem responds to their ...
plus
18.09.2007 – 08:24
Alliance for Better Bone Health
Actonel Halves Risk of Fracture in Osteoporotic Women With History of Hip Fracture
Honolulu, Hawaii (ots/PRNewswire) - New data show that Actonel(R) 5mg (risedronate sodium tablets) reduces the risk of clinical fractures by half versus placebo over three years in postmenopausal women with osteoporosis who have suffered a previous hip fracture(1)- a group of patients at high risk of a subsequent fracture. These results are from a retrospective ...
plus

14.09.2007 – 15:40
Novagali Pharma
Novagali Pharma Announces the Update of its "Document De Base" With the French Securities Market Authority ("Autorité des marchés financiers" - AMF)
Evry, France (ots/PRNewswire) - - Not for Distribution in the United States, Canada or Japan Novagali Pharma, an emerging ophthalmic pharmaceutical company, announces that the update of its document de base was filed on September 12th , 2007 to the Autorité des marchés financiers (AMF). This update ...
plus
13.09.2007 – 09:32
Roche Pharmaceuticals
Roche Launches Another Large Study With PEGASYS Plus COPEGUS
Basel, Switzerland (ots/PRNewswire) - - PROPHESYS Will Identify Factors That Influence Early Response to Treatment Roche announces the start of a large multinational observational study, called PROPHESYS, in patients with hepatitis C (HCV). This international cohort study will evaluate the important factors that give hepatitis C patients the best chance of treatment success with PEGASYS(R) (peginterferon ...
plus
06.09.2007 – 16:31
AstraZeneca GmbH
AstraZeneca Announces First Patient Enrolled in Head-to-Head Comparison of CRESTOR/Ezetimibe With Simvastatin/Ezetimibe
London (ots/PRNewswire) - AstraZeneca today announced enrolment of the first patient in the new GRAVITY study (Gauging the lipid effects of RosuvAstatin plus ezetimibe Versus sImvastatin plus ezetimibe TherapY). GRAVITY is a clinical trial examining the impact on LDL-cholesterol ('bad' cholesterol) levels in ...
plus
06.09.2007 – 09:05
Boehringer Ingelheim
Boehringer Ingelheim to Initiate First Phase III Pivotal Study for New Oncology Compound BIBW 2992(i)
Ingelheim, Germany (ots/PRNewswire) - - New Data on BIBW 2992(i), a Potent, Irreversible, Second-Generation Oral Signal Transduction Inhibitor Provides Glimpse of Next Chapter in Lung Cancer Care - For Non-US Media Boehringer Ingelheim announced today from the 12th World Conference on Lung Cancer (WCLC) that the company plans to commence Phase III ...
plus
05.09.2007 – 22:27
IsoTis OrthoBiologics
IsoTis Files Definitive Proxy Statement
Irvine, California (ots/PRNewswire) - - Special Stockholders Meeting to Approve Merger With Integra on October 11, 2007 IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced the filing of a definitive proxy statement with the U.S. Securities and Exchange Commission ("SEC") in connection with the IsoTis-Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") combination. ...
plus
05.09.2007 – 11:08
REACH Registry
REACH Registry Highlights That Patients With Peripheral Arterial Disease (PAD) Suffer High Rates of Heart Attack, Stroke, Hospitalization, and Death
Vienna, Austria (ots/PRNewswire) - - New analyses presented in Europe for the first time underscores REACH implications for individuals with leg artery blockages - Findings suggest the need for earlier, more aggressive therapeutic intervention New analyses from the REACH Registry presented at the ...
plus

04.09.2007 – 17:19
Roche Pharmaceuticals
Roche's Tarceva(R) Delivers Longer Life for Lung Cancer Patients
Seoul, Korea (ots/PRNewswire) - Patients worldwide with advanced lung cancer can expect longer survival according to new data from the TRUST study presented at the 12th World Conference on Lung Cancer (WCLC) in Seoul, Korea. These new worldwide observations show that patients suffering from non-small cell lung cancer (NSCLC) and treated with Tarceva (erlotinib) in routine clinical practice are experiencing ...
plus
03.09.2007 – 10:04
Boehringer Ingelheim
Suffering in Silence - The Real Impact of the Last Taboo
Ingelheim, Germany (ots/PRNewswire) - Constipation is a condition that we are all familiar with, however, according to new international research from Dulcolax(R), constipation actually affects much more than just bowel movements and can have a severely detrimental impact on people's quality of life, in some cases comparable to that experienced by people suffering from more serious ailments. The Dulcolax(R) survey ...
plus
03.09.2007 – 00:04
sanofi-aventis Group
New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
Paris (ots/PRNewswire) - Sanofi-aventis announced today that one year findings from the landmark ExTRACT-TIMI 25 and STEEPLE studies confirm clear net clinical benefit for patients with acute ST-segment elevation myocardial infarction (STEMI) for Lovenox(R) vs Unfractionnated Heparin (UFH). The ExTRACT-TIMI ...
plus
31.08.2007 – 07:35
shaPE Capital AG
euro adhoc: shaPE Capital AG / quarterly or semiannual financial statement / shaPE with solid first half-year 2007 results
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 6-month report 31.08.2007 Pfaeffikon SZ, 31 August 2007 --- In the first half year of 2007 shaPE achieved continued solid results as illustrated by the 17.5% increase in the Net Asset Value ...
plus
29.08.2007 – 12:06
Callisto Pharmaceuticals. Inc.
American Stock Exchange Accepts Callisto Pharamceuticals' Plan of Compliance and Extension to Regain Compliance with Standards
New York (ots/PRNewswire) - Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders and diseases, today announced that the staff of the American Stock Exchange ("AMEX") has reviewed the Company's plan of compliance ...
plus
29.08.2007 – 10:51
AstraZeneca GmbH
AstraZeneca's Once-Daily SEROQUEL XR(TM) Extended-Release Tablets Approved in Netherlands for the Acute and Long Term Treatment of Schizophrenia
London (ots/PRNewswire) - - For International Medical Journalists Only AstraZeneca today announced the Netherlands regulatory authority MEB (Medicines Evaluation Board) has approved SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets, a once-daily medicine for the treatment of schizophrenia in ...
plus

24.08.2007 – 15:06
AGA Medical Corporation
AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Minneapolis (ots/PRNewswire) - AGA Medical Corporation ("AGA") announced today that it has received U.S. Food and Drug Administration (FDA) and European CE Mark approvals for the AMPLATZER Vascular Plug II ("vascular plug II"). The AMPLATZER Vascular Plug II expands the AGA family of occlusion devices designed to embolize, or close blood vessel and blood ...
plus
24.08.2007 – 11:41
Roche Pharmaceuticals
Avastin Approved in Europe for First-line Treatment of Patients With Advanced Lung Cancer
Basel, Switzerland (ots/PRNewswire) - - First Medicine Shown to Extend Survival Beyond One Year in Previously Untreated Lung Cancer Patients Avastin (bevacizumab), Roche's innovative anti-cancer drug, was approved today in Europe for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC), in combination with platinum-based ...
plus
22.08.2007 – 15:02
Roche Pharmaceuticals
Updated WHO Bird Flu (H5N1) Management Guidance Reinforces Tamiflu as First Line Treatment
Basel, Switzerland (ots/PRNewswire) - The World Health Organization (WHO) has reinforced that Tamiflu (oseltamivir) is the primary recommended antiviral of choice in managing patients infected with H5N1 in updated guidance published on the WHO website today. Experts believe that a human influenza pandemic is imminent and could be triggered by the highly pathogenic ...
plus
22.08.2007 – 13:06
SemBioSys, Genetics Inc
SemBioSys Updates Apo AI Development Program
Calgary, Canada (ots/PRNewswire) - - Canadian Biotechnology Company Confirms Commercial Expression Levels of Apo AI Milano Variant and Clarifies Status of Native Apo AI SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today updated a release issued on July 12, 2007 announcing that the Company had achieved ...
plus
20.08.2007 – 14:31
IsoTis OrthoBiologics
IsoTis Receives FDA Clearance for Accell Family of Products
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it received a letter dated August 15, 2007 from the US Food and Drug Administration ("FDA"), clearing the Accell Family of Products for marketing in the US as Class II medical devices. The Accell Family of Products includes Accell 100, Accell Connexus and Accell Total Bone Matrix, as well as ...
plus
20.08.2007 – 09:33
Wyeth Pharmaceuticals
Wyeth Receives Approval from European Medicines Agency for New BeneFix Features
Maidenhead, England (ots/PRNewswire) - - Enhancements Provide Haemophilia B Patients with a Simpler and More Convenient Preparation Process for Recombinant Factor IX - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has received approval from the European Medicines Agency (EMEA) for new enhancements for BeneFix(R) nonacog ...
plus

09.08.2007 – 13:06
Callisto Pharmaceuticals. Inc.
Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
New York (ots/PRNewswire) - Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and inflammatory diseases, announced today the addition of two sites to its Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine ...
plus
07.08.2007 – 12:15
IsoTis OrthoBiologics
IsoTis Reports Q2 2007 Results and Recommends Stockholders Approve Merger With Integra LifeSciences
Irvine, California (ots/PRNewswire) - IsoTis, Inc (NASDAQ: ISOT), an orthobiologics company, today reported its results for the second quarter and six months ended June 30, 2007. Product revenues were $10.4 million for the second quarter of 2007, representing a 4% decrease over product revenues of $10.8 million for the second quarter of 2006. For the first six ...
plus
07.08.2007 – 12:05
Integra LifeSciences Holdings Corporation and IsoTis, Inc.
Integra LifeSciences and IsoTis to Combine
Plainsboro, New Jersey and Irvine, California (ots/PRNewswire) - - Creating a Global Leader in Orthobiologics Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") and IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis") announced today a definitive agreement whereby Integra would acquire IsoTis in an all cash transaction. This strategic combination, unanimously approved by the Board of Directors of IsoTis, ...
plus
03.08.2007 – 16:19
IsoTis OrthoBiologics
IsoTis to Release Second Quarter 2007 Results on August 7
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDQ: ISOT), a leading orthobiologics company, will release its 2007 second quarter results before opening of trading on Tuesday, August 7, 2007. To discuss these results, the Company will conduct a conference call at 4:00 p.m. (Eastern Time) / 1:00 p.m. (Pacific Time)/ 10:00 p.m. (Central European Time). Dial in details will be provided in the Q2 2007 release on ...
plus
02.08.2007 – 15:06
Isotechnika Inc.
FDA Allows Long Term Use of ISA247 in Isotechnika Phase 2b Kidney Transplant Trial
Edmonton, Canada (ots/PRNewswire) - Isotechnika today announced that the Company has received permission from the Food and Drug Administration of the United States (FDA) for the long term use of ISA247 in patients currently participating in the Company's Phase 2b kidney transplant (PROMISE) trial. The Company previously announced in June that it had also ...
plus
01.08.2007 – 21:55
MDS Pharma Services
MDS Pharma Services Expands Development & Regulatory Services in Europe
King Of Prussia, Pennsylvania (ots/PRNewswire) - MDS Pharma Services, a leading provider of innovative drug discovery and development solutions, announced today the expansion of its Development & Regulatory Services (DRS) business in Europe. MDS Pharma Services will now offer full-service DRS consulting services to support development of new drugs and ...
plus

Précédent58596061626364656667Suivant